Search
for
Sort by
Research 211–240 of 1000+
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Tofacitinib in the Management of Alopecia Universalis
- Successful Treatment of Canities Subita with Baricitinib
- Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
- DEVELOPING NEW DUAL-ACTION ANTIVIRAL/ANTI-INFLAMMATORY SMALL MOLECULES FOR COVID-19 TREATMENT USING IN SILICO AND IN-VITRO APPROACHES
- Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
- Alopecia universalis following human papillomavirus vaccine administration: a case report
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- Janus Kinase inhibitors in dermatology: a review
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Role of janus kinase inhibitors in the treatment of alopecia areata
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Janus kinase inhibitors for alopecia areata
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors